Clinical and Ethical Considerations in Pharmacogenetic Testing: Views of Physicians in 3 "Early Adopting" Departments of Psychiatry

被引:51
作者
Hoop, Jinger G. [1 ]
Lapid, Maria I. [2 ]
Paulson, Rene M. [3 ]
Roberts, Laura Weiss [1 ]
机构
[1] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA
[2] Mayo Clin, Rochester, MN USA
[3] Elite Res, Denton, TX USA
关键词
SEROTONIN TRANSPORTER GENE; PROMOTER POLYMORPHISM; PERSONALITY-TRAITS; ASSOCIATION; METAANALYSIS; DEPRESSION; EFFICACY; RECOMMENDATIONS; ATTITUDES; BEHAVIOR;
D O I
10.4088/JCP.08m04695whi
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: Pharmacogenetic testing for polymorphisms affecting drug response and metabolism is now clinically available, and its use in psychiatry is expected to become more widespread. Currently, few clinical and ethical standards exist for the use of these new tests. As a step toward building consensus about testing, we assessed the attitudes and practices of psychiatrists at 3 academic departments of psychiatry where pharmacogenetic testing is clinically available. We hypothesized that testing would be used primarily in treatment-resistant illness and that clinicians would believe such tests carried little risk. Method: Residents and faculty at 3 departments of psychiatry considered to be "early adopters" of pharmacogenetic testing were invited during the academic year 2006-2007 to complete an Internet-based survey, including questions regarding clinical practices and opinions about testing utility, risks, and necessary safeguards. Results: The 75 respondents had ordered pharmacogenetic testing a mean of 20.86 times in the previous 12 months. Testing was judged most useful in cases of treatment-resistant depression and medication intolerance. There was a lack of consensus about the risks of testing, particularly the risk of secondary information about disease susceptibility. Respondents endorsed the use of several safeguards, including confidentiality, pretest and posttest counseling, and informed consent, but consensus about other safeguards was lacking. Women and those who had not ordered testing in the prior year were more concerned about risks and need for safeguards than were men and those who had recently ordered testing. Conclusions: Physicians at early adopting departments of psychiatry endorsed the clinical utility of pharmacogenetic testing and the use of some patient safeguards, but showed a lack of consensus about other safeguards and risks. J Clin Psychiatry 2010;71(6):745-753 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
引用
收藏
页码:745 / 753
页数:9
相关论文
共 35 条
[1]  
[Anonymous], 1993, J Med Genet, V30, P1028
[2]  
Appelbaum Paul S, 2004, J Psychiatr Pract, V10, P343, DOI 10.1097/00131746-200411000-00002
[3]   The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14094 cases and 17 760 controls [J].
Bagos, Pantelis G. ;
Elefsinioti, Antigoni L. ;
Nikolopoulos, Georgios K. ;
Hamodrakas, Stavros J. .
JOURNAL OF HYPERTENSION, 2007, 25 (03) :487-500
[4]   Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors [J].
Berg, Alfred O. ;
Piper, Margaret ;
Armstrong, Katrina ;
Botkin, Jeffrey ;
Calonge, Ned ;
Haddow, James ;
Hayes, Maxine ;
Kaye, Celia ;
Phillips, Kathryn A. ;
Richards, Carolyn Sue ;
Scott, Joan A. ;
Strickland, Ora L. ;
Teutsch, Steven .
GENETICS IN MEDICINE, 2007, 9 (12) :819-825
[5]   CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].
Bradford, LD .
PHARMACOGENOMICS, 2002, 3 (02) :229-243
[6]   A meta-analysis of response rates in Web- or internet-based surveys [J].
Cook, C ;
Heath, F ;
Thompson, RL .
EDUCATIONAL AND PSYCHOLOGICAL MEASUREMENT, 2000, 60 (06) :821-836
[7]   Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP4502C19 [J].
De Leon, J ;
Armstrong, SC ;
Cozza, KL .
PSYCHOSOMATICS, 2006, 47 (01) :75-85
[8]   Genetic exceptionalism in medicine: Clarifying the differences between genetic and nongenetic tests [J].
Green, MJ ;
Botkin, JR .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :571-575
[9]   Pharmacogenetic testing: not as simple as it seems [J].
Haga, Susanne B. ;
Burke, Wylie .
GENETICS IN MEDICINE, 2008, 10 (06) :391-395
[10]  
Hoop J.G., 2008, Genetics in Medicine